bluebird bio (BLUE) Competitors $4.67 -0.18 (-3.71%) Closing price 04:00 PM EasternExtended Trading$4.65 -0.02 (-0.43%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLUE vs. GOSS, CRGX, PLX, HUMA, ZYBT, CDTX, TVGN, SOPH, CRDF, and ANNXShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Gossamer Bio (GOSS), CARGO Therapeutics (CRGX), Protalix BioTherapeutics (PLX), Humacyte (HUMA), Zhengye Biotechnology (ZYBT), Cidara Therapeutics (CDTX), Tevogen Bio (TVGN), SOPHiA GENETICS (SOPH), Cardiff Oncology (CRDF), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. bluebird bio vs. Gossamer Bio CARGO Therapeutics Protalix BioTherapeutics Humacyte Zhengye Biotechnology Cidara Therapeutics Tevogen Bio SOPHiA GENETICS Cardiff Oncology Annexon Gossamer Bio (NASDAQ:GOSS) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Which has preferable earnings & valuation, GOSS or BLUE? Gossamer Bio has higher revenue and earnings than bluebird bio. Gossamer Bio is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M1.54-$179.82M-$0.26-2.99bluebird bio$83.81M0.55-$211.91M-$45.54-0.10 Do analysts recommend GOSS or BLUE? Gossamer Bio presently has a consensus target price of $7.75, suggesting a potential upside of 897.43%. bluebird bio has a consensus target price of $44.60, suggesting a potential upside of 855.03%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than bluebird bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk & volatility, GOSS or BLUE? Gossamer Bio has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Is GOSS or BLUE more profitable? Gossamer Bio has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Gossamer Bio's return on equity of -127.28% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% bluebird bio -565.74%-322.46%-53.17% Do insiders and institutionals have more ownership in GOSS or BLUE? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by company insiders. Comparatively, 1.4% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor GOSS or BLUE? In the previous week, bluebird bio had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for bluebird bio and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.89 beat bluebird bio's score of 1.05 indicating that Gossamer Bio is being referred to more favorably in the media. Company Overall Sentiment Gossamer Bio Very Positive bluebird bio Positive Does the MarketBeat Community believe in GOSS or BLUE? bluebird bio received 887 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 70.62% of users gave bluebird bio an outperform vote while only 66.67% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15466.67% Underperform Votes7733.33% bluebird bioOutperform Votes104170.62% Underperform Votes43329.38% SummaryGossamer Bio beats bluebird bio on 13 of the 18 factors compared between the two stocks. Remove Ads Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.61M$2.74B$5.17B$7.35BDividend YieldN/A1.52%5.35%4.27%P/E Ratio-0.1229.6221.8317.55Price / Sales0.54412.64351.6389.75Price / CashN/A168.6838.1534.64Price / Book0.133.466.163.81Net Income-$211.91M-$72.06M$3.19B$247.05M7 Day Performance-4.72%-6.61%-3.79%-3.56%1 Month Performance18.25%-20.66%-2.56%-8.46%1 Year Performance-80.42%-35.02%3.43%-6.47% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio2.6067 of 5 stars$4.67-3.7%$44.60+855.0%-80.8%$45.72M$83.81M-0.12520Positive NewsGOSSGossamer Bio3.8016 of 5 stars$0.82+2.6%$7.75+844.4%-11.9%$186.46M$114.70M-2.56180Positive NewsGap DownCRGXCARGO Therapeutics2.8238 of 5 stars$4.03+0.2%$15.00+272.2%-80.9%$185.59MN/A-0.95116Positive NewsGap DownHigh Trading VolumePLXProtalix BioTherapeutics1.8254 of 5 stars$2.34-2.1%$15.00+541.0%+77.3%$182.60M$53.40M-18.00200Gap DownHUMAHumacyte2.5987 of 5 stars$1.26-6.7%$13.71+988.4%-49.7%$182.50M$1.57M-0.94150Positive NewsZYBTZhengye BiotechnologyN/A$3.85-10.3%N/AN/A$181.59M$189.75M0.00278Gap DownCDTXCidara Therapeutics4.095 of 5 stars$16.52+0.5%$39.14+136.9%-0.2%$180.94M$1.28M-0.6590Analyst ForecastGap DownTVGNTevogen Bio2.9348 of 5 stars$1.03+2.0%$7.10+589.3%-52.3%$180.30MN/A0.003News CoverageGap DownSOPHSOPHiA GENETICS2.5552 of 5 stars$2.69-2.5%$6.80+152.8%-40.8%$179.39M$65.17M-2.47520CRDFCardiff Oncology1.1215 of 5 stars$2.69-2.2%$11.67+333.7%-53.9%$178.95M$683,000.00-2.8620Gap DownHigh Trading VolumeANNXAnnexon2.4415 of 5 stars$1.63-3.6%$18.67+1,045.2%-77.2%$178.83MN/A-1.5560News Coverage Remove Ads Related Companies and Tools Related Companies Gossamer Bio Competitors CARGO Therapeutics Competitors Protalix BioTherapeutics Competitors Humacyte Competitors Zhengye Biotechnology Competitors Cidara Therapeutics Competitors Tevogen Bio Competitors SOPHiA GENETICS Competitors Cardiff Oncology Competitors Annexon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLUE) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLUE Stock Free BLUE Stock Alerts